A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials

Sleep Epidemiology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles